Darbepoetin
Sponsors
St. Bartholomew's Hospital, Groupe Francophone des Myelodysplasies, Bayer, NICHD Neonatal Research Network, VA Office of Research and Development
Conditions
AnemiaBlood PressureChronic Kidney DiseaseDecompensated CirrhosisDecompensated Liver CirrhosisMyelodysplastic SyndromesNeonatalNeurocognitive
Phase 2
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
NCT00234143
Start: 2004-10-31Target: 360Updated: 2009-03-12
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
NCT00443339
Start: 2006-12-31End: 2008-07-31Target: 99Updated: 2007-05-17
Long-term Pre-dialysis Extension in Europe and Asia Pacific
CompletedNCT02055482
Start: 2014-06-24End: 2016-12-12Updated: 2017-11-22
Mechanisms of EPO-induced Hypertension
TerminatedNCT03810911
Start: 2021-01-04End: 2025-07-31Updated: 2025-12-15
Phase 3
Unknown Phase
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Not yet recruitingNCT07002827
Start: 2025-05-30End: 2026-04-30Target: 60Updated: 2025-06-04
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Not yet recruitingNCT07131280
Start: 2025-09-30End: 2031-12-31Target: 110Updated: 2025-08-20